ATEC Reports Second Quarter Financial Results – Ortho Spine News
Alphatec Holdings (Nasdaq: ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year. Surgical revenue was $196 million, up 17%, driven by 20% case volume growth. Adjusted EBITDA was $36 million, 17% of revenue. The company reaffirmed its 2026 outlook: revenue about $882 million and adjusted EBITDA about $140 million.
How this was made
The 30-second read
Why it matters
Traders can update models around operating leverage (adjusted EBITDA margin up 420 bps) and cash generation (positive free cash flow, TTM free cash flow positivity) while monitoring the webcast for any additional detail not included in the excerpt.
Market read
A company-specific earnings and guidance update with raised adjusted EBITDA and continued surgical case volume growth, likely driving near-term positioning into the webcast.
What to watch
The excerpt emphasizes non-GAAP adjusted EBITDA and free cash flow positivity, but does not provide GAAP earnings, segment margins, or any litigation updates that could affect quality of earnings.
Background
Alphatec Holdings (ATEC) is a spine-focused surgical solutions provider; this is its Q2 2026 results release with full-year outlook reaffirmation and adjusted EBITDA guidance increase.
Ticker impact
ATEC reported Q2 revenue of $214M (+15% YoY), surgical revenue $196M (+17%), and raised full-year adjusted EBITDA guidance to ~$140M.
Moderate upside bias for near-term trading as guidance is increased and profitability metrics improved.
The article provides multiple concrete operating metrics (revenue, surgical growth, adjusted EBITDA margin, free cash flow positivity) plus a specific guidance increase, which typically supports sentiment and positioning ahead of the webcast.
Market effects
Signals continued demand and adoption in spine surgery technology, potentially supportive for other spine-focused medtech names.
Limited direct regional spillover; primarily company-specific medtech sentiment.
Low global macro linkage; relevance mainly to US-listed medtech investors.
Counterpoint
Revenue outlook is only reaffirmed, so upside may be capped if investors expected a larger top-line upgrade or clearer EPS/GAAP profitability detail.
Key entities
- companyAlphatec Holdings, Inc.
Reported Q2 2026 financial results and reaffirmed 2026 revenue outlook while increasing adjusted EBITDA guidance.
- executivePat Miles
CEO/Chairman quoted on case volume growth, surgeon adoption, and profitability.